Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.68 USD
Change Today -0.11 / -0.93%
Volume 928.4K
NKTR On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 5:20 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert B. Chess

AgeTotal Calculated CompensationThis person is connected to 139 board members in 6 different organizations across 6 different industries.

See Board Relationships
58$377,713

Background*

Mr. Robert B. Chess, also known as Rob, served as the Chief Executive Officer of OPX Biotechnologies, Inc. Mr. Chess served as the President and Chief Executive Officer of Nektar Therapeutics from March 17, 2006 to January 15, 2007 and served as its Interim President and Acting Chief Executive Officer from March 17, 2006 to January 15, 2007. Mr. Chess served as an Interim President and Chief Executive Officer of Nektar Therapeutics, from 1992 to 2000. He served as Co-Chief ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

Director
Director
Director
Chairman
Director
1992-Present
Chairman
2000-2006
Former Director
2004-Present
Independent Director and Member of Nominating & Corporate Governance Committee
2007-2009
Former Director

Education*

MBA
Harvard Business School
BSE
California Institute of Technology

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$110,750
Total Calculated Compensation$377,713
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.68 USD -0.11

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$557.2K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$620.1K
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.